ElectroCore Operating Expenses 2017-2025 | ECOR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ElectroCore operating expenses from 2017 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ElectroCore operating expenses from 2017 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70B
Zoetis (ZTS)	$68.3B
Takeda Pharmaceutical (TAK)	$47.7B
Daiichi Sankyo, - (DSNKY)	$47.6B
BeOne Medicines - (ONC)	$35.2B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$17.1B
Shionogi (SGIOY)	$15.2B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.6B
Eisai (ESAIY)	$9.2B
Madrigal Pharmaceuticals (MDGL)	$8.2B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.4B
Ionis Pharmaceuticals (IONS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Hikma Pharmaceuticals Plc (HKMPF)	$5.3B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$3.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.4B
Ocular Therapeutix (OCUL)	$2.2B
Endo (NDOI)	$1.8B